Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Abroad (travel likely)RecruitingPHASE1

Conditions

Non-small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Rochester, Rochester, New York, United States
Contact: Study coordinator (Megan Baumgart) · wcictoresearch@urmc.rochester.edu
Contact: Principal Investigator (Megan Baumgart)
University of Rochester, Rochester, New York, United States

Study leads

Megan Baumgart
Principal Investigator
University of Rochester

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Non-Small Cell Lung Cancer · Chemotherapy · PD1 Antibody

Abroad (travel likely)RecruitingPHASE1

Zhengzhou, China

AB122 Platform Study

Advanced or Metastatic Solid Tumor · Pancreatic Ductal Adenocarcinoma · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1

Aichi, Japan · Chiba, Japan

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Tucson, United States

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

Non-small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Jinan, China